AI-guided health recommendations for gastric cancer prevention

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study aims to implement and validate the AIDA tool, an AI-powered assistant designed to help clinicians diagnose precancerous inflammation and suggest personalized therapeutic strategies. The study is conducted in two phases: the first focuses on risk stratification and personalized recommendations, while the second involves the development and testing of a mechanistic model. By integrating AI technology, the study seeks to enhance patient monitoring and contribute to gastric cancer prevention efforts.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects ≥ 18 years old with a diagnosis of GIM or previous or current H. pylori infection, to whom a gastroscopy is indicated within clinical care
* Availability of a signed informed consent form to participate in the study

Exclusion Criteria:

* Patients to whom an endoscopy is performed for the follow-up of another illness such as oesophageal varices and/or for therapy such as endoscopic dilation, feeding tube placement or endoscopic resection
* Subjects with a clinical diagnosis of gastric diseases other than GIM or GC
* Patients who have received antimicrobials during the four weeks prior to the endoscopy
* Patients who have received proton pump inhibitors and/or bismuth-based treatments at least two weeks prior to the endoscopy
* Subjects for whom clinical data are not available: H. pylori status, eradication treatment, sex, age, tobacco smoking, and first-degree family history of gastric cancer
* Subjects who lack the mental capacity to understand the nature and requirements of the study and who lack the ability to give informed consent

Where it's running

• Hospital Clínico Universitario de Valencia
  Valencia, Spain Recruiting

Study contacts

• Principal investigator: Tania Fleitas, MD, PhD — Fundación para la Investigación del Hospital Clínico de Valencia
• Study coordinator: Ana Miralles Marco, PhD
• Email: amiralles@incliva.es
• Phone: +34 689567412

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding Saccharomyces boulardii to bismuth quadruple therapy for H. pylori rescue

  This tests whether adding the probiotic Saccharomyces boulardii to bismuth-containing quadruple therapy helps adults whose H. pylori infection did not clear after prior treatments.

  Recruiting Phase 4 Xijing Hospital of Digestive Diseases · Xi'an, Shaanxi · NCT07139366

• Assessing H. pylori infection rates and antibiotic resistance in Germany

  This study is trying to find out how common H. pylori infections are in Germany and if the bacteria are resistant to antibiotics, so doctors can better treat patients.

  Recruiting Technical University of Munich · Munich · NCT05561504

• Observational study on gastric precancerous conditions

  This study looks at people who are at higher risk for stomach cancer to see how conditions like atrophic gastritis and intestinal metaplasia develop over time.

  Recruiting Stanford University · Stanford, California · NCT04191551

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.